A multicentre single arm non-comparative Phase-III study to evaluate the safety and tolerability of single intramuscular dose of Biological Eâ??s Vi-capsular Polysaccharide-CRM197 Conjugate Typhoid Vaccine in â?¥6 months old infants to 45 years old adults. - None
Latest Information Update: 16 Jun 2020
At a glance
- Drugs Typhoid vaccine Vi conjugate (Primary)
- Indications Typhoid
- Focus Adverse reactions; Registrational
- Sponsors Biological E Limited
Most Recent Events
- 19 May 2020 Status changed from not yet recruiting to recruiting.
- 30 Jan 2020 New trial record